Johnson & Johnson (JNJ, $128.85) Loses Motion to Reverse a $4.7 Billion Verdict
Shares of the health-care conglomerate Johnson & Johnson dropped another 1% on Thursday. This happened after the company lost its motion to reverse a $4.7 billion jury verdict awarded to women who blamed ovarian cancer on asbestos in the company’s baby powder and other talc products.
According to the report published by New York Times, the ruling was upheld by a circuit court judge in Missouri, Rex Burlison, who oversaw the trial in the case. In his ruling Judge Rex Burlison said there was “substantial evidence” of “particularly reprehensible conduct” by J&J. He further added that the executives were also aware of the presence of asbestos in products that they knowingly targeted for sale to mothers and babies, knew of the damage that their products can cause, and misrepresented the safety of these products for decades.
With the stock now down nearly 13% so far this month, the company is inline to record its worst month since February 2009.
Losing this motion doesn’t mean that the $4.69 billion payout is imminent, as the company still has an entire set of appeals process to exhaust. But this ~$4.7 billion law suit, apart from the reputational damage, has also resulted into the company losing more than $50 billion in market value since damning articles were published by Reuters and The New York Times.
JNJ in upward trend: 10-day moving average broke above 50-day moving average on June 11, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on June 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on JNJ as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on June 23, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
JNJ moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in of 351 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 258 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JNJ broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.859) is normal, around the industry mean (19.568). P/E Ratio (26.801) is within average values for comparable stocks, (26.482). Projected Growth (PEG Ratio) (3.006) is also within normal values, averaging (15.849). Dividend Yield (0.023) settles around the average of (0.031) among similar stocks. P/S Ratio (5.845) is also within normal values, averaging (3.939).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement